Close Menu

This Heart's Not for Sale

Premium

Framingham Genomics Medicine, a company founded with $21 million in venture capital and led in part by Fred Ledley, former CEO and president of Variagenics, plans to close its doors. Formed to organize data from the 52-year-old Framingham Heart Study, the company was forced to disband after Boston University and the National Heart, Lung, and Blood Institute denied it access to the data.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Researchers representing scientists and students of Chinese descent voice their concerns about recent US policies and rhetoric.

Wired reports that researchers have shown they could reprogram a DNA-based computer.

Researchers say increased diversity in genomic studies will benefit all, PBS NewsHour reports.

In Science this week: whole-genome sequencing of single sperm cells, and more.